BridgeBio Pharma (2CL) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2CL Analyst Ratings

Strong Buy

18 Buy

1 Hold

0 Sell

Based on 19 analysts giving stock ratings to

BridgeBio

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2CL Stock 12 Month Forecast

Average Price Target

€93.29

▲(24.47% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is €93.29 with a high forecast of €136.39 and a low forecast of €80.79. The average price target represents a 24.47% change from the last price of €74.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"€39","88":"€88","137":"€137","63.5":"€63.5","112.5":"€112.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136.39222553,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€136.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.2930544761111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€93.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.79284697,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€80.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,63.5,88,112.5,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.35,74.50709427153845,79.66418854307692,84.82128281461537,89.97837708615384,95.1354713576923,100.29256562923075,105.44965990076922,110.60675417230769,115.76384844384614,120.9209427153846,126.07803698692307,131.23513125846154,{"y":136.39222553,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.35,71.1917734212393,73.03354684247863,74.87532026371794,76.71709368495726,78.55886710619657,80.40064052743588,82.2424139486752,84.08418736991452,85.92596079115384,87.76773421239315,89.60950763363246,91.45128105487179,{"y":93.2930544761111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.35,70.2302189976923,71.11043799538461,71.99065699307693,72.87087599076922,73.75109498846153,74.63131398615384,75.51153298384615,76.39175198153846,77.27197097923077,78.15218997692307,79.03240897461538,79.91262797230769,{"y":80.79284697,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.37,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€136.39

Average Price Target€93.29

Lowest Price Target€80.79

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

€104.25

Buy

39.09%

Upside

Reiterated

07/24/26

Analyst Reiterates Buy on BridgeBio, Maintaining $120 Price Target as Late-Stage Rare Disease Pipeline Advances

Myles Minter

William Blair

―

Buy

―

Reiterated

07/22/26

BridgeBio: Buy Rating Reaffirmed on Strong Encaleret Data and Multi‑Asset Launch Outlook

Jason Zemansky

Bank of America Securities

€87.74

Buy

17.07%

Upside

Reiterated

07/22/26

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (NASDAQ: BBIO), Agilon Health (NYSE: AGL) and Sanofi (Other OTC: SNYNF)

Eric Joseph

Citi

€71.24→€80.79

Hold

7.80%

Upside

Assigned

07/17/26

BridgeBio price target raised to $93 from $82 at CitiBridgeBio price target raised to $93 from $82 at Citi

Biren Amin

Piper Sandler

€96.43

Buy

28.66%

Upside

Reiterated

07/09/26

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

Eliana Merle

Barclays

€136.39

Buy

81.98%

Upside

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (NASDAQ: TVRD), Teva Pharmaceutical (NYSE: TEVA) and BridgeBio Pharma (NASDAQ: BBIO)

Luca Issi

RBC Capital

€86.87

Buy

15.91%

Upside

Reiterated

07/07/26

RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Andrew Tsai

Jefferies

€86.87

Buy

15.91%

Upside

Reiterated

07/06/26

BridgeBio Pharma (BBIO) Gets a Buy from Jefferies

Salim Syed

Mizuho Securities

€83.4

Buy

11.27%

Upside

Reiterated

06/21/26

BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities

Tiago Fauth

Raymond James

€108.59→€85.14

Buy

13.59%

Upside

Reiterated

06/17/26

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), BridgeBio Pharma (NASDAQ: BBIO) and Guardant Health (NASDAQ: GH)

Whitney Ijem

Canaccord Genuity

€90.35

Buy

20.55%

Upside

Initiated

06/03/26

BridgeBio initiated with a Buy at CanaccordBridgeBio initiated with a Buy at Canaccord

Sean Laaman

Morgan Stanley

€81.66→€85.14

Buy

13.59%

Upside

Reiterated

05/27/26

Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data

Anupam Rama

J.P. Morgan

€86.87

Buy

15.91%

Upside

Reiterated

05/12/26

BridgeBio shares have 'clear path' to $90s, says JPMorganBridgeBio shares have 'clear path' to $90s, says JPMorgan

Danielle Brill

Truist Financial

€88.61

Buy

18.23%

Upside

Reiterated

05/11/26

Analysts Offer Insights on Healthcare Companies: Codexis (NASDAQ: CDXS), Irhythm Technologies (NASDAQ: IRTC) and BridgeBio Pharma (NASDAQ: BBIO)

Derek Archila

Wells Fargo

€85.14

Buy

13.59%

Upside

Reiterated

05/09/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and BridgeBio Pharma (NASDAQ: BBIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

€104.25

Buy

39.09%

Upside

Reiterated

07/24/26

Analyst Reiterates Buy on BridgeBio, Maintaining $120 Price Target as Late-Stage Rare Disease Pipeline Advances

Myles Minter

William Blair

―

Buy

―

Reiterated

07/22/26

BridgeBio: Buy Rating Reaffirmed on Strong Encaleret Data and Multi‑Asset Launch Outlook

Jason Zemansky

Bank of America Securities

€87.74

Buy

17.07%

Upside

Reiterated

07/22/26

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (NASDAQ: BBIO), Agilon Health (NYSE: AGL) and Sanofi (Other OTC: SNYNF)

Eric Joseph

Citi

€71.24→€80.79

Hold

7.80%

Upside

Assigned

07/17/26

BridgeBio price target raised to $93 from $82 at CitiBridgeBio price target raised to $93 from $82 at Citi

Biren Amin

Piper Sandler

€96.43

Buy

28.66%

Upside

Reiterated

07/09/26

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

Eliana Merle

Barclays

€136.39

Buy

81.98%

Upside

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (NASDAQ: TVRD), Teva Pharmaceutical (NYSE: TEVA) and BridgeBio Pharma (NASDAQ: BBIO)

Luca Issi

RBC Capital

€86.87

Buy

15.91%

Upside

Reiterated

07/07/26

RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

Andrew Tsai

Jefferies

€86.87

Buy

15.91%

Upside

Reiterated

07/06/26

BridgeBio Pharma (BBIO) Gets a Buy from Jefferies

Salim Syed

Mizuho Securities

€83.4

Buy

11.27%

Upside

Reiterated

06/21/26

BridgeBio Pharma (BBIO) Receives a Buy from Mizuho Securities

Tiago Fauth

Raymond James

€108.59→€85.14

Buy

13.59%

Upside

Reiterated

06/17/26

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (NYSE: IQV), BridgeBio Pharma (NASDAQ: BBIO) and Guardant Health (NASDAQ: GH)

Whitney Ijem

Canaccord Genuity

€90.35

Buy

20.55%

Upside

Initiated

06/03/26

BridgeBio initiated with a Buy at CanaccordBridgeBio initiated with a Buy at Canaccord

Sean Laaman

Morgan Stanley

€81.66→€85.14

Buy

13.59%

Upside

Reiterated

05/27/26

Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data

Anupam Rama

J.P. Morgan

€86.87

Buy

15.91%

Upside

Reiterated

05/12/26

BridgeBio shares have 'clear path' to $90s, says JPMorganBridgeBio shares have 'clear path' to $90s, says JPMorgan

Danielle Brill

Truist Financial

€88.61

Buy

18.23%

Upside

Reiterated

05/11/26

Analysts Offer Insights on Healthcare Companies: Codexis (NASDAQ: CDXS), Irhythm Technologies (NASDAQ: IRTC) and BridgeBio Pharma (NASDAQ: BBIO)

Derek Archila

Wells Fargo

€85.14

Buy

13.59%

Upside

Reiterated

05/09/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and BridgeBio Pharma (NASDAQ: BBIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

3 Months

Greg HarrisonScotiabank

Success Rate

14/16 ratings generated profit

Average Return

+29.51%

Copying Greg Harrison's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +29.51% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

16/16 ratings generated profit

Average Return

+81.35%

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +81.35% per trade.

2 Years

Greg HarrisonScotiabank

Success Rate

16/16 ratings generated profit

Average Return

+135.40%

Copying Greg Harrison's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +135.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2CL Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2CL has received 17 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 2CL average Analyst price target in the past 3 months is 93.29.

Each month's total comprises the sum of three months' worth of ratings.

2CL Financial Forecast

2CL Earnings Forecast

Currently, no earnings data available.

2CL Sales Forecast

Currently, no sales data available.

2CL Stock Forecast FAQ

What is DE:2CL’s average 12-month price target, according to analysts?

Based on analyst ratings, BridgeBio Pharma Inc’s 12-month average price target is 93.29.

What is DE:2CL’s upside potential, based on the analysts’ average price target?

BridgeBio Pharma Inc has 24.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BridgeBio Pharma Inc a Buy, Sell or Hold?

BridgeBio Pharma Inc has a consensus rating of Strong Buy, which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.

What is BridgeBio Pharma Inc’s share price target?

The average share price target for BridgeBio Pharma Inc is 93.29. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €136.39 ,and the lowest forecast is €80.79. The average share price target represents 24.47% Increase from the current price of €74.95.

What do analysts say about BridgeBio Pharma Inc?

BridgeBio Pharma Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of BridgeBio Pharma Inc?

To buy shares of DE:2CL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BridgeBio Pharma (2CL) Stock Forecast & Price Target

2CL Analyst Ratings

2CL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BridgeBio Pharma

2CL Analyst Recommendation Trends

2CL Financial Forecast

2CL Earnings Forecast

2CL Sales Forecast

2CL Stock Forecast FAQ

Detailed List of Analyst Forecasts